Showing 25 to 30 of 30 results
Pfizer Stock Up 5% on Positive 2025 Outlook
Pfizer's stock rose 5% on December 17, 2024, after projecting $61-$64 billion in 2025 revenue and $2.80-$3.00 adjusted earnings per share, driven by acquisitions and cost-cutting to offset declining Covid-19 vaccine sales.
Pfizer Stock Up 5% on Positive 2025 Outlook
Pfizer's stock rose 5% on December 17, 2024, after projecting $61-$64 billion in 2025 revenue and $2.80-$3.00 adjusted earnings per share, driven by acquisitions and cost-cutting to offset declining Covid-19 vaccine sales.
Progress
36% Bias Score
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Despite Reduced COVID-19 Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the year ending November 2023, down from previous years due to decreased COVID-19 vaccine and treatment sales, but still comparable to pre-pandemic levels; the subsidiary manages operations for most Pfizer entities outside the U.S.
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Despite Reduced COVID-19 Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the year ending November 2023, down from previous years due to decreased COVID-19 vaccine and treatment sales, but still comparable to pre-pandemic levels; the subsidiary manages operations for most Pfizer entities outside the U.S.
Progress
40% Bias Score
Pfizer Stock Plunges 50% Amidst Falling Sales and Vaccine Concerns
Pfizer stock is down 50% since early 2022 to $26, driven by a 42% fall in 2023 sales to $58.5 billion following the Covid-19 pandemic and concerns over new leadership's stance on vaccines, despite efforts to cut costs and develop new drugs.
Pfizer Stock Plunges 50% Amidst Falling Sales and Vaccine Concerns
Pfizer stock is down 50% since early 2022 to $26, driven by a 42% fall in 2023 sales to $58.5 billion following the Covid-19 pandemic and concerns over new leadership's stance on vaccines, despite efforts to cut costs and develop new drugs.
Progress
40% Bias Score
Pfizer's 2025 Forecast Meets Expectations Amidst Medicare Changes and Investor Scrutiny
Pfizer projects 2025 profits near analyst estimates, anticipating stable Covid-19 product sales despite a \$1 billion revenue reduction from Medicare changes and ongoing investor pressure following a 12% share decline this year.
Pfizer's 2025 Forecast Meets Expectations Amidst Medicare Changes and Investor Scrutiny
Pfizer projects 2025 profits near analyst estimates, anticipating stable Covid-19 product sales despite a \$1 billion revenue reduction from Medicare changes and ongoing investor pressure following a 12% share decline this year.
Progress
36% Bias Score
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...
Progress
40% Bias Score
Antimicrobial Resistance: A Global Health Crisis
This article examines the growing threat of antimicrobial resistance and proposes innovative funding models to encourage the development of new antibiotics.
Antimicrobial Resistance: A Global Health Crisis
This article examines the growing threat of antimicrobial resistance and proposes innovative funding models to encourage the development of new antibiotics.
Progress
40% Bias Score
Showing 25 to 30 of 30 results